Which has preferable valuation and earnings, SOLV or MDLN?

Solventum has higher earnings, but lower revenue than Medline. Solventum is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solventum $8.26B 1.55 $1.56B $8.16 9.09 Medline $29.14B 1.59 $1.16B $0.32 110.31

Is SOLV or MDLN more profitable?

Solventum has a net margin of 17.33% compared to Medline's net margin of 0.00%. Solventum's return on equity of 23.51% beat Medline's return on equity. Company Net Margins Return on Equity Return on Assets Solventum 17.33% 23.51% 7.63% Medline N/A N/A N/A

Does the media favor SOLV or MDLN?

In the previous week, Medline had 14 more articles in the media than Solventum. MarketBeat recorded 17 mentions for Medline and 3 mentions for Solventum. Solventum's average media sentiment score of 0.25 beat Medline's score of 0.15 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medline 2 Very Positive mention(s) 1 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SOLV or GEHC?

In the previous week, GE HealthCare Technologies had 6 more articles in the media than Solventum. MarketBeat recorded 9 mentions for GE HealthCare Technologies and 3 mentions for Solventum. GE HealthCare Technologies' average media sentiment score of 1.36 beat Solventum's score of 0.25 indicating that GE HealthCare Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GE HealthCare Technologies 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SOLV or PHG?

Solventum currently has a consensus target price of $84.25, suggesting a potential upside of 13.64%. Given Solventum's stronger consensus rating and higher probable upside, equities research analysts clearly believe Solventum is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solventum 1 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.50 Koninklijke Philips 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to SOLV or PHG?

In the previous week, Solventum had 1 more articles in the media than Koninklijke Philips. MarketBeat recorded 3 mentions for Solventum and 2 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 0.50 beat Solventum's score of 0.25 indicating that Koninklijke Philips is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ZBH or SOLV?

In the previous week, Zimmer Biomet had 5 more articles in the media than Solventum. MarketBeat recorded 8 mentions for Zimmer Biomet and 3 mentions for Solventum. Zimmer Biomet's average media sentiment score of 1.19 beat Solventum's score of 0.25 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, SOLV or SNN?

Solventum has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solventum $8.26B 1.55 $1.56B $8.16 9.09 Smith & Nephew SNATS $6.16B 2.04 $625M N/A N/A

Solventum (SOLV) Competitors

$74.14 +0.58 (+0.79%)

Closing price 03:58 PM Eastern

Extended Trading

$74.00 -0.14 (-0.20%)

As of 06:30 PM Eastern

Compare

SOLV vs. MDLN, GEHC, PHG, ZBH, and SNN

Should you buy Solventum stock or one of its competitors? MarketBeat compares Solventum with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Solventum include Medline (MDLN), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), and Smith & Nephew SNATS (SNN). These companies are all part of the "medical equipment" industry.

How does Solventum compare to Medline?

Solventum (NYSE:SOLV) and Medline (NASDAQ:MDLN) are both large-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Solventum has higher earnings, but lower revenue than Medline. Solventum is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.26B	1.55	$1.56B	$8.16	9.09
Medline	$29.14B	1.59	$1.16B	$0.32	110.31

Solventum currently has a consensus target price of $84.25, indicating a potential upside of 13.64%. Medline has a consensus target price of $50.54, indicating a potential upside of 43.17%. Given Medline's stronger consensus rating and higher possible upside, analysts clearly believe Medline is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Medline	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.79

In the previous week, Medline had 14 more articles in the media than Solventum. MarketBeat recorded 17 mentions for Medline and 3 mentions for Solventum. Solventum's average media sentiment score of 0.25 beat Medline's score of 0.15 indicating that Solventum is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medline	2 Very Positive mention(s)	1 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solventum has a net margin of 17.33% compared to Medline's net margin of 0.00%. Solventum's return on equity of 23.51% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Medline	N/A	N/A	N/A

Summary

Medline beats Solventum on 8 of the 14 factors compared between the two stocks.

How does Solventum compare to GE HealthCare Technologies?

Solventum (NYSE:SOLV) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

In the previous week, GE HealthCare Technologies had 6 more articles in the media than Solventum. MarketBeat recorded 9 mentions for GE HealthCare Technologies and 3 mentions for Solventum. GE HealthCare Technologies' average media sentiment score of 1.36 beat Solventum's score of 0.25 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GE HealthCare Technologies	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum has a net margin of 17.33% compared to GE HealthCare Technologies' net margin of 9.10%. Solventum's return on equity of 23.51% beat GE HealthCare Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
GE HealthCare Technologies	9.10%	20.46%	5.73%

GE HealthCare Technologies has higher revenue and earnings than Solventum. Solventum is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.26B	1.55	$1.56B	$8.16	9.09
GE HealthCare Technologies	$20.63B	1.41	$2.08B	$4.18	15.24

Solventum currently has a consensus target price of $84.25, indicating a potential upside of 13.64%. GE HealthCare Technologies has a consensus target price of $80.20, indicating a potential upside of 25.86%. Given GE HealthCare Technologies' stronger consensus rating and higher possible upside, analysts clearly believe GE HealthCare Technologies is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
GE HealthCare Technologies	0 Sell rating(s)	9 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53

82.1% of GE HealthCare Technologies shares are owned by institutional investors. 0.2% of Solventum shares are owned by company insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Solventum has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Summary

GE HealthCare Technologies beats Solventum on 11 of the 16 factors compared between the two stocks.

How does Solventum compare to Koninklijke Philips?

Solventum (NYSE:SOLV) and Koninklijke Philips (NYSE:PHG) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Solventum had 1 more articles in the media than Koninklijke Philips. MarketBeat recorded 3 mentions for Solventum and 2 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 0.50 beat Solventum's score of 0.25 indicating that Koninklijke Philips is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum currently has a consensus target price of $84.25, suggesting a potential upside of 13.64%. Given Solventum's stronger consensus rating and higher probable upside, equities research analysts clearly believe Solventum is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Solventum has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Koninklijke Philips has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Solventum has a net margin of 17.33% compared to Koninklijke Philips' net margin of 5.49%. Solventum's return on equity of 23.51% beat Koninklijke Philips' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Koninklijke Philips	5.49%	13.51%	5.48%

Solventum has higher earnings, but lower revenue than Koninklijke Philips. Solventum is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.26B	1.55	$1.56B	$8.16	9.09
Koninklijke Philips	$20.17B	1.30	$1.01B	$1.17	22.74

13.7% of Koninklijke Philips shares are held by institutional investors. 0.2% of Solventum shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Solventum beats Koninklijke Philips on 11 of the 16 factors compared between the two stocks.

How does Solventum compare to Zimmer Biomet?

Zimmer Biomet (NYSE:ZBH) and Solventum (NYSE:SOLV) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

88.9% of Zimmer Biomet shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by insiders. Comparatively, 0.2% of Solventum shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Zimmer Biomet presently has a consensus target price of $102.70, suggesting a potential upside of 17.18%. Solventum has a consensus target price of $84.25, suggesting a potential upside of 13.64%. Given Zimmer Biomet's higher probable upside, equities research analysts clearly believe Zimmer Biomet is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Solventum has lower revenue, but higher earnings than Zimmer Biomet. Solventum is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.41B	2.02	$705.20M	$3.85	22.76
Solventum	$8.26B	1.55	$1.56B	$8.16	9.09

Solventum has a net margin of 17.33% compared to Zimmer Biomet's net margin of 9.05%. Solventum's return on equity of 23.51% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Solventum	17.33%	23.51%	7.63%

Zimmer Biomet has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Solventum has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

In the previous week, Zimmer Biomet had 5 more articles in the media than Solventum. MarketBeat recorded 8 mentions for Zimmer Biomet and 3 mentions for Solventum. Zimmer Biomet's average media sentiment score of 1.19 beat Solventum's score of 0.25 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Zimmer Biomet beats Solventum on 9 of the 17 factors compared between the two stocks.

How does Solventum compare to Smith & Nephew SNATS?

Solventum (NYSE:SOLV) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

25.6% of Smith & Nephew SNATS shares are held by institutional investors. 0.2% of Solventum shares are held by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Solventum has a net margin of 17.33% compared to Smith & Nephew SNATS's net margin of 0.00%. Solventum's return on equity of 23.51% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Smith & Nephew SNATS	N/A	N/A	N/A

Solventum has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Solventum has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.26B	1.55	$1.56B	$8.16	9.09
Smith & Nephew SNATS	$6.16B	2.04	$625M	N/A	N/A

In the previous week, Solventum had 3 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 3 mentions for Solventum and 0 mentions for Smith & Nephew SNATS. Solventum's average media sentiment score of 0.25 beat Smith & Nephew SNATS's score of 0.00 indicating that Solventum is being referred to more favorably in the media.

Company	Overall Sentiment
Solventum	Neutral
Smith & Nephew SNATS	Neutral

Solventum currently has a consensus price target of $84.25, suggesting a potential upside of 13.64%. Smith & Nephew SNATS has a consensus price target of $30.93, suggesting a potential upside of 4.41%. Given Solventum's stronger consensus rating and higher probable upside, analysts plainly believe Solventum is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Summary

Solventum beats Smith & Nephew SNATS on 11 of the 14 factors compared between the two stocks.

Get Solventum News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SOLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SOLV vs. The Competition

Export

Metric	Solventum	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$12.84B	$8.67B	$6.47B	$23.14B
Dividend Yield	N/A	1.73%	2.68%	4.06%
P/E Ratio	9.09	23.42	24.71	31.08
Price / Sales	1.55	16.78	491.85	108.37
Price / Cash	8.39	13.96	27.92	18.65
Price / Book	2.55	6.21	10.82	4.65
Net Income	$1.56B	$174.80M	$3.56B	$1.07B
7 Day Performance	-3.13%	2.03%	1.67%	-1.04%
1 Month Performance	-3.62%	1.54%	0.43%	0.18%
1 Year Performance	1.27%	10.30%	32.84%	24.25%

Solventum Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SOLV Solventum	3.4907 of 5 stars	$74.14 +0.8%	$84.25 +13.6%	-0.1%	$12.84B	$8.26B	9.09	20,000
MDLN Medline	4.0753 of 5 stars	$37.33 +2.0%	$50.54 +35.4%	N/A	$48.09B	$28.43B	116.66	45,000
GEHC GE HealthCare Technologies	4.9388 of 5 stars	$64.76 -0.6%	$80.21 +23.9%	-14.9%	$29.65B	$20.63B	15.49	54,000	Positive News Analyst Forecast
PHG Koninklijke Philips	2.6467 of 5 stars	$26.69 +0.9%	N/A	+20.9%	$25.48B	$20.17B	22.87	65,340	News Coverage
ZBH Zimmer Biomet	4.7332 of 5 stars	$88.15 -0.5%	$102.70 +16.5%	-4.3%	$17.13B	$8.23B	22.90	17,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SOLV) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solventum (SOLV) Competitors

SOLV vs. MDLN, GEHC, PHG, ZBH, and SNN

How does Solventum compare to Medline?

Summary

How does Solventum compare to GE HealthCare Technologies?

Summary

How does Solventum compare to Koninklijke Philips?

Summary

How does Solventum compare to Zimmer Biomet?

Summary

How does Solventum compare to Smith & Nephew SNATS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOLV vs. The Competition

Solventum Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Solventum (SOLV) Competitors

SOLV vs. MDLN, GEHC, PHG, ZBH, and SNN

How does Solventum compare to Medline?

Which has preferable valuation and earnings, SOLV or MDLN?

Do analysts recommend SOLV or MDLN?

Does the media favor SOLV or MDLN?

Is SOLV or MDLN more profitable?

Summary

How does Solventum compare to GE HealthCare Technologies?

Does the media favor SOLV or GEHC?

Is SOLV or GEHC more profitable?

Which has stronger earnings and valuation, SOLV or GEHC?

Do analysts rate SOLV or GEHC?

Do insiders & institutionals hold more shares of SOLV or GEHC?

Which has more risk and volatility, SOLV or GEHC?

Summary

How does Solventum compare to Koninklijke Philips?

Does the media refer more to SOLV or PHG?

Do analysts recommend SOLV or PHG?

Which has more volatility & risk, SOLV or PHG?

Is SOLV or PHG more profitable?

Which has preferable valuation and earnings, SOLV or PHG?

Do institutionals and insiders hold more shares of SOLV or PHG?

Summary

How does Solventum compare to Zimmer Biomet?

Do insiders & institutionals hold more shares of ZBH or SOLV?

Do analysts recommend ZBH or SOLV?

Which has higher earnings & valuation, ZBH or SOLV?

Is ZBH or SOLV more profitable?

Which has more volatility & risk, ZBH or SOLV?

Does the media prefer ZBH or SOLV?

Summary

How does Solventum compare to Smith & Nephew SNATS?

Do institutionals & insiders have more ownership in SOLV or SNN?

Is SOLV or SNN more profitable?

Which has more volatility & risk, SOLV or SNN?

Which has better earnings and valuation, SOLV or SNN?

Does the media favor SOLV or SNN?

Do analysts rate SOLV or SNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOLV vs. The Competition

Solventum Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools